Introduction
Early initiation of dual antiplatelet therapy, including a loading dose of a P2Y 12 inhibitor, is recommended for all patients presenting with acute myocardial infarction (MI). 1, 2 However some patients may be already taking clopidogrel for secondary prevention of MI or stroke, or after coronary stent placement or peripheral vascular intervention. For patients who are already on clopidogrel therapy, reloading with 600 mg of clopidogrel leads to increased platelet inhibition compared with the 75 mg dose, 3 with less inter-individual variability, 4 but the clinical significance of this is unknown for patients with NSTEMI and STEMI. Large randomized trials of P2Y 12 inhibitors for treatment of MI have either excluded patients on home clopidogrel therapy [5] [6] [7] or treated these patients with the daily clopidogrel dose only. 8, 9 A randomized trial of 242 patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) and planned percutaneous coronary intervention (PCI) showed a benefit of clopidogrel reloading compared with a maintenance dose, driven primarily by periprocedural MI. 10 However, the optimal reloading strategy for all MI patients remains unclear and is not addressed by clinical practice guidelines. 1, 2 Furthermore, the potential for increased bleeding associated with reloading has not been assessed in a large cohort. Acute Coronary Treatment Intervention Outcomes Network
Registry-Get With the Guidelines TM (ACTION Registry-GWTG) is the largest ongoing MI registry in the United States and offers a unique opportunity to characterize treatment patterns and outcomes of MI patients on chronic clopidogrel therapy. Our objectives were to (i) describe the prevalence of pre-admission P2Y 12 inhibitor therapy among acute MI patients and inpatient clopidogrel dosing strategies; (ii) compare clinical and treatment characteristics of patients reloaded with clopidogrel vs. treated with the maintenance dose; and (iii) examine the association of reloading with in-hospital major bleeding and mortality.
Methods

Data source
The National Cardiovascular Data Registry V R (NCDR) ACTION Registry-GWTG is a large ongoing US quality improvement registry. Participating hospitals submit detailed inpatient data for acute MI patients, including demographics, clinical characteristics, treatment, and in-hospital outcomes using a standardized set of data elements and definitions. 11 Data quality is assessed via real-time validation checks as well as annual data audits. Registry participation at each hospital is either approved by an institutional review board or deemed not subject to review based on individual site determinations.
Study population
In ACTION Registry-GWTG, a total of 599 281 patients were admitted to PCI-capable hospitals from July 2009 to December 2014. We used this full population to examine the prevalence of pre-admission P2Y 12 inhibitor use among patients presenting with MI. For our assessment of clopidogrel reloading in the first 24 h of admission, we sequentially excluded patients not taking clopidogrel prior to admission (515 796), those with documented contraindication to catheterization (13 083), or to treatment with clopidogrel, prasugrel, or ticagrelor (2781), those who did not receive P2Y 12 inhibitor within the first 24 h of presentation (10 591), and those with missing dose or timing information for a P2Y 12 inhibitor (703). Finally, we excluded patients switched to prasugrel or ticagrelor within 24 h of admission (4803). Our final study population consisted of 51 524 patients at 735 hospitals ( Figure 1) . Among NSTEMI patients, reloading clopidogrel may be more likely if a patient has had a recent PCI and therefore the potential for stent thrombosis. We performed a pre-specified sensitivity analysis to assess outcomes among patients with PCI within 1 year prior to presentation Figure 1 Consort diagram. Starting with a large population of MI patients from a national quality improvement registry, we focused on patients eligible for reloading of clopidogrel at the time of admission. We therefore excluded patients without prior to admission clopidogrel use, a contraindication to invasive management or use of a P2Y 12 inhibitor, and patients that received either no P2Y 12 inhibitor or prasugrel/ticagrelor at the time of admission. NSTEMI, non-ST segment elevation myocardial infarction; STEMI, ST segment myocardial infarction.
(n = 10 465) because guidelines recommend anti-platelet therapy for 1 year after drug-eluting stent implantation. We also pre-specified a sensitivity analysis including patients undergoing angiography within 24 h of presentation (20 108) , since reloading may be more common in the setting of an early invasive strategy.
Finally, we repeated the analysis after stratifying our population by bleeding risk. We analysed the risk of major bleeding associated with clopidogrel loading for both high (top tertile of ACTION bleeding risk score) and low (bottom two tertiles of ACTION bleeding risk score) risk patients.
Data definitions
All demographic, clinical, and treatment variables were obtained from the ACTION Registry-GWTG data collection form. Detailed definitions for data elements of the registry are available at https://www. ncdr.com/webncdr/action/home/datacollection (10 May 2017). Preadmission use of clopidogrel, prasugrel, and ticagrelor was captured as a home medication on the data collection form. Use and dose of clopidogrel within the first 24 h of medical contact (including patients transferred in from another medical facility) was captured; a loading dose of clopidogrel was defined as > _300 mg.
We examined the in-hospital outcomes of major bleeding and mortality. ACTION-Registry GWTG major bleeding is defined as any of the following: absolute haemoglobin drop of at least 4 g/dL; intracranial haemorrhage; retroperitoneal bleeding; transfusion in the setting of baseline haemoglobin > _ 9 or < 9 g/dL with a witnessed bleeding event.
Statistical analysis
To examine the overall use of pre-admission P2Y 12 inhibitors, the full population was used. The percentage of pre-admission use of any P2Y 12 inhibitor, and percentage of each individual P2Y 12 inhibitor respectively, was calculated semi-annually. A Cochran-Armitage trend test was used to test the null hypothesis that home P2Y 12 inhibitor use is constant across the study period.
We used our final study population, stratified by STEMI vs. NSTEMI presentation due to markedly different rates of reloading, to compare demographic, clinical, and in-hospital treatment variables of patients receiving a reloading dose vs. maintenance dose. Continuous variables were described using median and interquartile range and categorical variables were summarized using percentage. A v 2 test was used for categorical variables and the Wilcoxon rank sum test was used for continuous variables.
Rates of in-hospital major bleeding and mortality were compared between patients with and without clopidogrel reloading. We used inverse probability weighted propensity methods to compare adjusted outcomes. First, we modelled the association of clopidogrel reloading strategy with patient and hospital variables using a logistic regression for STEMI and NSTEMI patients, respectively. Model covariates were chosen a priori as potentially related to choice of reloading strategy and/or inhospital outcomes and included demographics (age, sex, race, insurance status), clinical variables and comorbidities [body mass index, current/ recent smoker, hypertension, dyslipidaemia, dialysis, chronic lung disease, diabetes, prior MI, prior congestive heart failure (CHF), prior PCI, prior CABG, atrial fibrillation or flutter, cerebrovascular disease, peripheral arterial disease], home medications (aspirin, warfarin, beta-blocker, ACE inhibitor, angiotensin-receptor blocker, statin), presentation variables (signs of CHF, cardiogenic shock, cardiac arrest, heart rate, systolic blood pressure, thrombolytic therapy (STEMI only), primary PCI (STEMI only), PCI (NSTEMI only), initial creatinine, initial haemoglobin, peak troponin), in-hospital treatment [use of anticoagulation (unfractionated heparin, low molecular weight heparin, bivalrudin), diagnostic cath, number of diseased vessels, drug-eluting stent use, coronary artery bypass graft surgery (CABG)], hospital characteristics (region, teaching status, total beds), and year of presentation. Continuous covariates were modelled using restricted cubic spline transformations to allow for possible nonlinearity. 12 After using logistic regression to estimate propensity of clopidogrel reloading, we calculated standardized inverse treatment probability weights and checked the covariate balance achieved between groups in the weighted population. Measures of covariate imbalance were acceptably low for all model covariates after weighting (Cramer's phi < 0.05 for categorical variables and R 2 < 0.0025 for continuous covariates). Finally, we performed weighted logistic regression with generalized estimating equations with exchangeable working correlation structure to account for hospital clustering to determine the adjusted odds ratio for major bleeding or mortality by reloading strategy. The percentage of missing values was less than 1% for all variables included in the multivariable model. Missing values of the continuous variables were imputed to the STEMI/NSTEMI and gender-specific median of the non-missing values, and missing values of the categorical variables were imputed to their most common value.
All analyses were performed using SAS software (version 9.3 or 9.4; SAS, Cary, NC) and statistical significance was determined by a 2-sided P-value <0.05.
Results
From July 2009 to December 2014, 599 281 patients were admitted with acute MI. Of these, 232 926 (38.9%) presented with STEMI and 366 355 (61.1%) presented with NSTEMI. Pre-admission P2Y 12 inhibitor use was 9.3% among STEMI patients and 18.9% among NSTEMI patients. Among patients with pre-admission P2Y 12 inhibitor use, clopidogrel was the most common agent (91.9%), though rates of clopidogrel use declined slightly in later years in concert with increasing use of prasugrel and ticagrelor (P-values for trends <0.001) (Figure 2) .
Among the 56 327 patients on home clopidogrel therapy who were eligible for cardiac catheterization, we excluded 4803 patients (8.5%) who were switched from clopidogrel to either prasugrel or ticagrelor. Among the remaining 51 524 patients who were continued on clopidogrel, reloading with a dose > _ 300 mg occurred in 19 513 (37.9%) of patients. Among the 12 366 patients with STEMI, 9369 (75.8%) received a loading dose (> _300 mg). Of 39 158 patients with NSTEMI, 10 144 (25.9%) were reloaded. In both STEMI and NSTEMI populations, reloaded patients were more likely to be younger, male and had lower rates of prior cardiovascular disease, diabetes, renal disease, and other comorbidities compared with patients not receiving a loading dose (<300 mg) ( Table 1) . Predicted risks of both in-hospital mortality and bleeding (as calculated from presenting characteristics by the ACTION mortality and bleeding risk scores, respectively) were lower for reloaded patients. Reloaded STEMI patients were more likely to be treated with primary PCI, and reloaded NSTEMI patients were more likely to have early angiography (<24 h) and PCI.
Among STEMI patients, clopidogrel reloading was not associated with an increased risk of major bleeding after inverse probability weighted propensity adjustment (OR 0.98, 95% CI 0.85-1.13). Rates of in-hospital death were lower among reloaded patients and this relationship remained significant after statistical adjustment (OR 0.80, 95% CI 0.66-0.96) ( Table 2 
Among NSTEMI patients, rates of in-hospital major bleeding and mortality were similar for patients treated with or without the loading dose. After statistical adjustment, reloading was not associated with a significant difference in mortality (OR 1.13, 95% CI 0.93-1.37) or major bleeding (OR 1.00, 95% CI 0.90- 1.11 ) when compared with no reloading. We then performed two sensitivity analyses to determine if reloading was associated with bleeding or death among NSTEMI patients with (i) PCI within the prior year (n = 10 465, 26.7% of total) or (ii) cardiac catheterization within 24 h of presentation (n = 20 108, 51.4% of total). There was no difference in outcomes associated with reloading clopidogrel in either of these subgroups after statistical adjustment (Table A1) .
Clopidogrel reloading was not associated with major bleeding among subgroups at highest risk of bleeding (top tertile of ACTION bleeding risk score) for STEMI (OR 1.06, 95% CI 0.85-1.31) or NSTEMI (OR 1.03, 95% CI 0.90- 1.19 ) patients. This was also the case among patients with lower baseline bleeding risk (bottom two tertiles).
Discussion
Clopidogrel reloading occurs frequently among patients who present with MI already on clopidogrel therapy, particularly among STEMI patients and those that are younger and have lower comorbidity burden. We did not observe an increased risk of major bleeding during hospitalization with clopidogrel reloading in either STEMI or NSTEMI patients. Reloading was associated with lower in-hospital mortality risk for patients with STEMI, but not NSTEMI. These findings from a large national registry indicate that clopidogrel reloading is common and likely safe for most MI patients.
Trends in P2Y 12 therapy
Patients already taking clopidogrel at the time of MI are a large and understudied population. Home P2Y 12 inhibitor use was 9.3 and 18.9% among patients presenting with STEMI and NSTEMI respectively, and remained stable throughout our study period, though these rates may increase in the future due to recent trial results demonstrating benefit of prolonged dual antiplatelet therapy. 13, 14 Patients on pre-admission clopidogrel may be at higher risk of adverse outcomes. In the TRILOGY randomized study of medically-treated patients with NSTE-ACS, the only large randomized controlled trial that included patients with prior clopidogrel use, these patients had higher rates of co-morbidities and prior ischaemic events, and a greater burden of vascular disease. The ischaemic event rates at 30 months after NSTE-ACS were elevated compared with patients not already taking clopidogrel. 9 Our study focused on patients already taking and continued on clopidogrel. Patients who were switched to prasugrel or ticagrelor may have had unmeasured factors prompting switch, and were excluded from this analysis. Overall, 38% of clopidogrel-treated patients were reloaded, but this was strongly influenced by STEMI (75% reloaded) vs. NSTEMI (26% reloaded) status. Reloading was associated with lower predicted bleeding risk, as assessed by the ACTION bleeding risk score, more frequent use of anticoagulants, and with an early invasive strategy (NSTEMI) or primary PCI (STEMI). This indicates that clinicians may be more likely to provide reloading for patients at lower perceived risk of bleeding and/or in the setting of possible PCI, though not necessarily those at highest risk for ischaemia.
Associations with bleeding and mortality
Variability in the current use of clopidogrel reloading may be due to the absence of clinical practice guideline recommendations and conflicting clinical trial data. Clinical trials have generally demonstrated that earlier and more potent platelet inhibition at the time of MI results in lower rates of ischaemic events, whether that is treatment with clopidogrel and aspirin compared with aspirin 
alone, 5,6 a higher loading dose of clopidogrel, 15 or use of a more potent anti-platelet agent. 7, 8 However, more recent studies have not shown a benefit for P2Y 12 inhibitor pre-treatment of patients with NSTEMI or STEMI. 16, 17 For clopidogrel-treated patients, high platelet reactivity is associated with increased risk of ischaemic events, 18 and there is significant variability in platelet response among patients treated with the maintenance dose. 19 Reloading 600 mg of clopidogrel in the setting of daily therapy results in additional reduction in platelet activity and less inter-individual variability. 3, 4 Reloading might therefore improve MI ischaemic outcomes, though at the potential cost of increased bleeding. The ARMYDA-4 RELOAD trial tested this theory among 503 PCI patients. While reloading did not reduce the primary endpoint of major adverse cardiovascular events (MACE) at 30 days among the full trial population, there was a potential benefit noted in the ACS subgroup. 20 10 A single centre observational study of 1368 patients on long-term clopidogrel therapy found no association of reloading with ischaemic or bleeding outcomes. 21 As previous randomized comparisons of reloading were conducted in small study populations, and without any STEMI patients, we leveraged the much larger cohort of MI patients in the ACTION Registry to examine the safety of clopidogrel reloading in current clinical practice. Rates of major bleeding were not higher for reloaded patients compared with patients treated with the maintenance dose, in both unadjusted and adjusted analysis accounting for clinical and treatment factors including invasive management strategy and use of other anti-thrombotic medications. This was true even among STEMI patients, nearly all of whom were invasively managed, among NSTEMI patients managed with angiography within 24 h, and for patients at higher risk for bleeding based on clinical factors (ACTION bleeding risk score). The findings of the ARMYDA randomized trials and our study are therefore complementary. The potential benefit of reduced peri-procedural MI shown in ARMYDA-8 RELOAD does not appear to come at the cost of increased bleeding in this large national cohort.
Though we could not assess peri-procedural MI in our study, reloading was associated with lower in-hospital mortality among patients with STEMI. This result should be interpreted with caution. Reloaded patients were more likely to have primary PCI, and were younger with fewer comorbid conditions. Clinicians may be selectively reloading patients with more acute disease but also greater likelihood of survival and recovery. Our study may not sufficiently adjust for this, and therefore overestimate the association of reloading with survival. Reloading could plausibly improve survival via a reduction in peri-procedural MI and/or acute stent thrombosis rates, but these are not reliably captured in the ACTION registry. Therefore, the finding of lower adjusted risk of mortality among STEMI patients is hypothesis generating, but may be related to residual confounding. These results should be further investigated by a prospective randomized study.
Reload strategy was not associated with mortality among NSTEMI patients, even those managed with an early invasive strategy or those with PCI within 1 year and therefore at higher risk for stent thrombosis. Overall rates of death were low (2.2%) among NSTEMI patients, and any potential benefit of reloading on ischaemic outcomes may have been insufficient to impact mortality.
Limitations
This study has several potential limitations. First, it is observational and thus cannot determine causality. Though we performed statistical adjustment for numerous clinical and procedural variables using inverse probability weighted propensity adjustment, unmeasured confounders cannot be excluded. Rationale for clinicians choosing to reload was not captured in the registry. In particular, we could not assess adherence to anti-platelet therapy prior to the index MI, and clinicians may be more likely to reload patients who report medication non-adherence. Additionally, we cannot determine the timing of clopidogrel dosing within the first 24 h. Patients with high ontreatment platelet reactivity may be expected to benefit most from clopidogrel reloading, but we could not assess this due to lack of platelet function testing data. However, platelet function testing data are rarely available to clinicians in routine clinical practice. 22 We excluded patients switched to prasugrel or ticagrelor on admission, since these agents were approved during the study period and may have been used selectively in certain patient populations or hospitals. Therefore we cannot evaluate a strategy of P2Y 12 agent switching as an alternative to clopidogrel treatment. Though prasugrel and ticagrelor are increasingly used, clopidogrel remains the dominant P2Y 12 agent in Europe and the US, 23, 24 and thus our results apply to a large contemporary patient population. Our analysis of bleeding was limited to major bleeds, and we did not assess post-discharge outcomes. Finally, our analysis is limited to hospitals participating in a quality improvement registry, and may not be representative of other hospitals in the United States or in other countries.
Conclusions
Patients presenting with MI already taking clopidogrel are frequently treated with an early loading dose of clopidogrel, especially when presenting with STEMI. Reloading is not associated with an increased risk of in-hospital major bleeding or mortality, and therefore could be safe for most patients. Further study of the potential benefit of reloading is needed to determine if this should be the preferred treatment strategy for this common clinical scenario. 
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